| Pack Size/Qty | Price | Unit Price | |
| 90 Rotacap/s | $31.00 | $0.35 | |
| 60 Rotacap/s | $24.00 | $0.40 | |
| 30 Rotacap/s | $15.00 | $0.50 |
Generic Name : Salmeterol and Fluticasone Propionate
Brand Name : Advair Rotacaps
Manufacturer Name : Cipla Ltd - Pharmaceutical Company
Product Code : CRX 280
Delivery Days : 10 to 15 working days
Strength : 250 mcg
Packaging : Rotacaps/s
Prescribed For : Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Reaction
Seroflo Rotacaps 50mcg/250mcg is a medication designed to manage and treat respiratory conditions, particularly asthma and chronic obstructive pulmonary disease (COPD). This combination inhaler contains two active ingredients, fluticasone propionate and salmeterol xinafoate, which work synergistically to provide a comprehensive approach to respiratory symptom control. In this detailed exploration, we will delve into the composition, mechanism of action, indications, dosage, potential side effects, and other pertinent aspects of Seroflo Rotacaps 50mcg/250mcg.
Each Seroflo Rotacap with a strength of 50mcg/250mcg comprises two key components: fluticasone propionate and salmeterol xinafoate. Fluticasone propionate, a corticosteroid, acts as an anti-inflammatory agent, reducing the inflammation in the airways, while salmeterol xinafoate, a long-acting beta-agonist, helps in bronchodilation, opening up the air passages.
The dual-action mechanism of Seroflo Rotacaps 50mcg/250mcg combines anti-inflammatory effects with bronchodilation. Fluticasone propionate suppresses the release of inflammatory mediators, such as histamines and leukotrienes, reducing inflammation in the airways. Simultaneously, salmeterol xinafoate stimulates beta-2 adrenergic receptors in the bronchial smooth muscles, leading to relaxation and widening of the air passages. This combined effect provides relief from symptoms such as wheezing, shortness of breath, and chest tightness associated with asthma and COPD.
Seroflo Rotacaps 50mcg/250mcg is primarily indicated for the regular maintenance treatment of asthma and COPD in patients aged 12 years and older. It is not intended for immediate relief of acute symptoms and should be used as part of a long-term management plan under the guidance of a healthcare professional.
The dosage of Seroflo Rotacaps 50mcg/250mcg is individualized based on the severity of the respiratory condition and the patient's response to treatment. Typically, the recommended dose is one Rotacap twice daily, in the morning and evening. The inhalation technique is crucial for optimal drug delivery. The Rotacaps should be used with an inhalation device called a Rotahaler, which punctures the capsule and disperses the medication for inhalation. Patients are advised to rinse their mouths after inhalation to minimize the risk of local side effects.
While Seroflo Rotacaps 50mcg/250mcg is generally well-tolerated, like any medication, it can cause side effects. Common side effects may include throat irritation, cough, headache, and fungal infections in the mouth. These effects are often mild and transient. However, more serious side effects, such as systemic corticosteroid effects, increased heart rate, and paradoxical bronchospasm, should be reported to a healthcare professional promptly.
Before initiating treatment with Seroflo Rotacaps 50mcg/250mcg, healthcare providers should assess the patient's medical history, including allergies, cardiovascular conditions, and existing respiratory infections. The medication is contraindicated in patients with hypersensitivity to any of its components and those with a history of hypersensitivity to milk proteins.
Special precautions are warranted in patients with certain pre-existing conditions, such as diabetes, hypokalemia, and hyperthyroidism. Additionally, healthcare providers must monitor patients regularly, especially when transitioning from systemic corticosteroid therapy to Seroflo Rotacaps, to avoid the risk of adrenal insufficiency.
Seroflo Rotacaps 50mcg/250mcg may interact with other medications, such as beta-blockers, tricyclic antidepressants, and monoamine oxidase inhibitors. Therefore, it is crucial for healthcare providers to be aware of the patient's complete medication history to prevent potential drug interactions.
In summary, Seroflo Rotacaps 50mcg/250mcg is a combination inhaler that offers a dual-action approach to managing asthma and COPD symptoms. By combining the anti-inflammatory effects of fluticasone propionate with the bronchodilator activity of salmeterol xinafoate, this medication provides comprehensive respiratory symptom control. While it is effective in improving quality of life for individuals with chronic respiratory conditions, it is essential to use the medication as prescribed and under the supervision of a healthcare professional. Regular monitoring and communication with the healthcare team are integral components of successful long-term management with Seroflo Rotacaps 50mcg/250mcg.
